GlaxoSmithKline PLC’s first-in-class anti-BCMA antibody-drug conjugate – which now has breakthrough therapy designation in the US for relapsed and refractory multiple myeloma – "serves notice that GSK is truly back in the oncology business", its divisional R&D head said in an interview.
GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate. GSK on Nov 2 said the agent received breakthrough...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)